<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684736</url>
  </required_header>
  <id_info>
    <org_study_id>TSK Sepsis</org_study_id>
    <nct_id>NCT00684736</nct_id>
  </id_info>
  <brief_title>Tryptophan, Serotonin and Kynurenine in Septic Shock</brief_title>
  <acronym>TSK</acronym>
  <official_title>Tryptophan, Serotonin and Kynurenine in Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Septic shock is a major cause of mortality and morbidity worldwide. Serotonin (5-HT) is&#xD;
      released by activated platelets into the circulation, and is mediator of endothelial&#xD;
      dysfunction. 5-HT metabolism is known in immune system via specific 5-HT receptor, also in&#xD;
      effects on the peripheral nervous system. Kinetic of 5-HT, tryptophan, kynurenine, MAO&#xD;
      activity and IDO activity in human septic shock was never investigated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Kinetics of 5-HT, 5-HIAA, kynurenine, tryptophan, HVA, VMA, DOPAC, Oestradiol, Cotinine and vasopressors</measure>
    <time_frame>Day-1, Day-2, Day-3, Day-7 and Day-14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Shock, Septic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were 18 years of age or older and had been hospitalized in our ICU were&#xD;
        prospectively enrolled in the study if they met all eligibility criteria. Inclusion&#xD;
        criteria were clinical evidence of infection, evidence of a systemic response to infection,&#xD;
        and the onset of shock within the previous 3 hours.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age above or equal to 18 years&#xD;
&#xD;
          -  Strong presumption clinical sepsis&#xD;
&#xD;
          -  Need for mechanical ventilation&#xD;
&#xD;
          -  Body temperature above 38°C or below 36°C&#xD;
&#xD;
          -  Heart rate above 90 bpm&#xD;
&#xD;
          -  Systolic blood pressure of &lt;90mm Hg despite adequate fluid replacement or a need for&#xD;
             vasopressors less than 3 hours&#xD;
&#xD;
          -  Presence of at least one of the following criteria:&#xD;
&#xD;
               -  Ratio of arterial oxygen tension over inspired fraction of oxygen of less than&#xD;
                  300 mm Hg&#xD;
&#xD;
               -  Urinary output below 0.5 mL per kg of bodyweight per h or below 30 mL/h (for at&#xD;
                  least 1 h)&#xD;
&#xD;
               -  Arterial lactate concentration above 2 mmol/L&#xD;
&#xD;
          -  Consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age below 18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Underlying disease with a poor prognosis, a life expectancy of less than 24 hours&#xD;
&#xD;
          -  Depression or melancholy&#xD;
&#xD;
          -  Neuropsychiatric diseases: Seizure, manic psychosis, Migraine, or Drug addiction&#xD;
&#xD;
          -  Neuroendocrine tumors&#xD;
&#xD;
          -  Obstructive cardiomyopathy or acute myocardial ischaemia&#xD;
&#xD;
          -  Pulmonary embolism&#xD;
&#xD;
          -  Advanced stage cancer, malignant haemopathy, or AIDS with a decision to withhold or&#xD;
             withdraw aggressive therapies&#xD;
&#xD;
          -  Inclusion in another clinical trial&#xD;
&#xD;
          -  Patient who receive before inclusion one of the following treatment known to modify&#xD;
             serotonin level: almotriptan, amitriptyline, amoxapine, citalopram, clomipramine,&#xD;
             clozapine, desipramine, dihydroergotamine, dolasetron, dosulepin, doxepin, eletriptan,&#xD;
             ergotamine, flunarizine, fluoxetine, fluvoxamine, granisetron, imipramine, indoramin,&#xD;
             interferon Alfa, interferon alfacon-1, interferon beta, iproniazid, maprotiline,&#xD;
             methysergide, mianserin, Milnacipran, mirtazapine, moclobemide, naratriptan,&#xD;
             olanzapine, ondansetron, oxetorone, paroxetine, pizotifen, risperidone, sertraline,&#xD;
             sumatriptan, tianeptine, trimipramine, tropisetron, venlafaxine,viloxazine,&#xD;
             zolmitriptan.&#xD;
&#xD;
          -  No consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Bédos, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Versailles Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Odile Spreux-Varoquaux, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Versailles Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthieu Henry-Lagarrigue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Versailles Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Versailles - André Mignot Hospital</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <last_update_submitted>August 7, 2008</last_update_submitted>
  <last_update_submitted_qc>August 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>Henry-Lagarrigue Matthieu/MD</name_title>
    <organization>Intensive Care Unit</organization>
  </responsible_party>
  <keyword>septic shock</keyword>
  <keyword>shock</keyword>
  <keyword>serotonin</keyword>
  <keyword>kynurenine</keyword>
  <keyword>tryptophan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

